Introducing Bispecifics for Extensive-Stage SCLC


Tarlatamab was given accelerated approval in May 2024 for extensive-stage small cell lung cancer (SCLC). How does this therapy work, and what was the important data the led to its approval?

  • What are the main adverse events to watch for, and do you manage them?
  • Are there any other clinical considerations, such as inpatient or outpatient dosing, when using a bispecific T-cell engager like tarlatamab?
  • Where does this therapy fit into your treatment algorithm for patients with SCLC?



Source link

Leave a Comment

Your email address will not be published. Required fields are marked *